abstract |
Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB 1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases. |